NO319163B1 - Transdermal therapeutic system that prevents abuse - Google Patents
Transdermal therapeutic system that prevents abuse Download PDFInfo
- Publication number
- NO319163B1 NO319163B1 NO20001492A NO20001492A NO319163B1 NO 319163 B1 NO319163 B1 NO 319163B1 NO 20001492 A NO20001492 A NO 20001492A NO 20001492 A NO20001492 A NO 20001492A NO 319163 B1 NO319163 B1 NO 319163B1
- Authority
- NO
- Norway
- Prior art keywords
- substance
- layer
- tts according
- active substance
- requirements
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 11
- 239000000126 substance Substances 0.000 claims description 29
- 239000013543 active substance Substances 0.000 claims description 19
- 235000019640 taste Nutrition 0.000 claims description 9
- 210000000214 mouth Anatomy 0.000 claims description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 4
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 claims description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 4
- 230000007935 neutral effect Effects 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 238000004925 denaturation Methods 0.000 claims description 3
- 230000036425 denaturation Effects 0.000 claims description 3
- 229940100640 transdermal system Drugs 0.000 claims description 3
- MXYUKLILVYORSK-UHFFFAOYSA-N (+/-)-allo-lobeline Natural products C1CCC(CC(=O)C=2C=CC=CC=2)N(C)C1CC(O)C1=CC=CC=C1 MXYUKLILVYORSK-UHFFFAOYSA-N 0.000 claims description 2
- MXYUKLILVYORSK-HBMCJLEFSA-N (-)-lobeline Chemical compound C1([C@@H](O)C[C@H]2N([C@H](CCC2)CC(=O)C=2C=CC=CC=2)C)=CC=CC=C1 MXYUKLILVYORSK-HBMCJLEFSA-N 0.000 claims description 2
- 241000189429 Angostura Species 0.000 claims description 2
- 235000001258 Cinchona calisaya Nutrition 0.000 claims description 2
- 206010013911 Dysgeusia Diseases 0.000 claims description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 2
- 206010028813 Nausea Diseases 0.000 claims description 2
- 241000779819 Syncarpia glomulifera Species 0.000 claims description 2
- 229910021529 ammonia Inorganic materials 0.000 claims description 2
- 239000003613 bile acid Substances 0.000 claims description 2
- 235000019658 bitter taste Nutrition 0.000 claims description 2
- 229960001948 caffeine Drugs 0.000 claims description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims description 2
- 230000007794 irritation Effects 0.000 claims description 2
- 229960002339 lobeline Drugs 0.000 claims description 2
- 229930013610 lobeline Natural products 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 210000004400 mucous membrane Anatomy 0.000 claims description 2
- 230000008693 nausea Effects 0.000 claims description 2
- 230000035515 penetration Effects 0.000 claims description 2
- 239000001739 pinus spp. Substances 0.000 claims description 2
- 229960000948 quinine Drugs 0.000 claims description 2
- 235000018553 tannin Nutrition 0.000 claims description 2
- 229920001864 tannin Polymers 0.000 claims description 2
- 239000001648 tannin Substances 0.000 claims description 2
- 229940111630 tea tree oil Drugs 0.000 claims description 2
- 239000010677 tea tree oil Substances 0.000 claims description 2
- 229940036248 turpentine Drugs 0.000 claims description 2
- 239000010410 layer Substances 0.000 claims 12
- 239000011247 coating layer Substances 0.000 claims 2
- 244000207543 Euphorbia heterophylla Species 0.000 claims 1
- 239000000853 adhesive Substances 0.000 claims 1
- 239000004744 fabric Substances 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 230000001055 chewing effect Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229940124326 anaesthetic agent Drugs 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 239000011928 denatured alcohol Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Anesthesiology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Electrotherapy Devices (AREA)
- Saccharide Compounds (AREA)
- Electrolytic Production Of Non-Metals, Compounds, Apparatuses Therefor (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Radiation-Therapy Devices (AREA)
Abstract
Description
Oppfinnelsen angår et transdermalt terapeutisk system for beskyttelse av en person mot kontaminering som følge av utillatelig oral anvendelse (applikasjon) av toksiske innholdsstoffer i et transdermalt terapeutisk system (TTS), som omfatter minst et virkestoffholdig, særlig hefteklebende utstyrt sjikt, så vel som minst et ytterligere baksjikt som er ugjennomslippelig for virkestoffet, så vel som en TTS med et denaturert (forbitret) stoff. The invention relates to a transdermal therapeutic system for the protection of a person against contamination as a result of impermissible oral use (application) of toxic ingredients in a transdermal therapeutic system (TTS), which comprises at least one active ingredient-containing, particularly adhesively equipped layer, as well as at least one additional back layer impermeable to the active substance, as well as a TTS with a denatured (bittered) substance.
I forbindelse med en rekke TTS foreligger det en akutt fare for at det kan inntreffe uønskede konsekvenser, når personer - det kan være av nye eller avtatte systemer - oralt tilføres et derfra løsbart virkestoff. For eksempel har små barn den egenskap å stikke alle interessante ting i munnen for suging eller tygging. Spesielt kan dette ikke forhindres, når barn tilfeldigvis lykkes i å få tilgang på slike systemer, særlig uten frigjøringsforing. In connection with a number of TTS, there is an acute danger that unwanted consequences may occur, when people - it may be from new or weakened systems - are orally administered an active substance that can be dissolved from it. For example, young children have the tendency to put all interesting things in their mouths for sucking or chewing. In particular, this cannot be prevented, when children accidentally succeed in gaining access to such systems, especially without a release liner.
Til nå har slike situasjoner riktignok ikke vært kjent, men dette blir i stadig større grad fryktet av legemiddelmyndighetene, som av den grunn har stilt forskjellige krav til barnesikre forpakninger. Faktisk har slike forpakninger blitt utviklet i forskjellig utforming. De beskytter imidlertid ikke mot at et barn tar et TTS i munnen, når pakningen en gang er åpnet, eller når et benyttet plaster på eller annen måte kommer i hånden. Spesielt i forbindelse med TTS med virkestoffer som bedøvelsesmidler, smertelindrende medikamenter, beroligende midler eller psykofarmaka kan et oralt misbruk føre til alvorlige helseskader. På den annen side kan også stoffmisbrukere forsøke å utløse slike virkestoffer fra transdermale terapeutiske systemer ved suging eller tygging. Until now, such situations have admittedly not been known, but this is increasingly feared by the pharmaceutical authorities, who have therefore set different requirements for child-resistant packaging. In fact, such packages have been developed in different designs. However, they do not protect against a child taking a TTS in the mouth, once the package has been opened, or when a used patch somehow gets into the hand. Especially in connection with TTS with active substances such as anaesthetics, pain-relieving drugs, sedatives or psychopharmaceuticals, oral abuse can lead to serious health damage. On the other hand, drug addicts can also try to release such active substances from transdermal therapeutic systems by sucking or chewing.
Det er allerede kjent å forbitre etylalkohol og dermed bringe den i handel som denaturert sprit. En forbitring av legemiddelvirkestoffer har derimot til nå ikke vært kjent. It is already known to embitter ethyl alcohol and thus market it as denatured alcohol. An embitterment of medicinal active substances, however, has not been known until now.
Oppfinnelsen legger oppgaven til grunn å stille til rådighet et trandermalt terapeutisk system og en anvendelse av samme for beskyttelse av en person av den type som er nevnt i innledningen i krav 1, slik at et oralt misbruk av forannevnte beskrevne type ikke er mulig, idet på den annen side en uheldig forandring av de terapeutiske virkestoffene i systemet unngås og likeledes at helseskader vil være utelukket ved utillatelig oral anvendelse. The invention is based on the task of making available a trandermal therapeutic system and an application of the same for the protection of a person of the type mentioned in the introduction in claim 1, so that an oral abuse of the type described above is not possible, since on on the other hand, an unfortunate change in the therapeutic active substances in the system is avoided and likewise that damage to health will be excluded in case of impermissible oral use.
Som løsning på oppgaven blir det foreslått et transdermalt terapeutisk system (TTS) ifølge oppfinnelsen, der et terapeutisk nøytralt og ikke interreagerende stoff med motbydelig smak blir blandet til. As a solution to the task, a transdermal therapeutic system (TTS) according to the invention is proposed, in which a therapeutically neutral and non-interreacting substance with a disgusting taste is mixed.
Det blir også i følge oppfinnelsen foreslått en anvendelse av et terapeutisk nøytralt stoff med motbydelig smak for fremstilling av et transdermalt system. According to the invention, it is also proposed to use a therapeutically neutral substance with a disgusting taste for the production of a transdermal system.
Fordi dette stoffet fremkaller en høyst ubehagelig og uønsket smaksopplevelse, vil en første oral kontakt med TTS i følge oppfinnelsen eller en av dens forbitrede sjikt føre til en spontan reaksjon, ved at tilsvarende plaster blir spyttet ut og på den måten vil bam og stoffmisbrukere hindres i utillatelig bruk ved oral anvendelse av virkestoffene som er inneholdt i plasteret. Because this substance induces a highly unpleasant and unwanted taste experience, a first oral contact with TTS according to the invention or one of its embittered layers will lead to a spontaneous reaction, in that the corresponding patch is spit out and in this way bam and drug addicts will be prevented from impermissible use by oral application of the active substances contained in the patch.
En utførelsesform foreslår at til forbitring av en TTS blir det anvendt et stoff, som forårsaker kvalme og dermed gjør avsmak på suging for oral anvendelse. One embodiment proposes that for exasperation of a TTS a substance is used, which causes nausea and thus makes sucking for oral use distasteful.
En utførelsesform av fremgangsmåten foreslår i følge oppfinnelsen at stoffet blir påført According to the invention, one embodiment of the method proposes that the substance is applied
i et separat, ekstremt tynt sjikt der sjiktet ikke er forhindrende for gjennomslipping av virkestoffet, på det virkestoffholdige sjiktet. in a separate, extremely thin layer where the layer does not prevent the penetration of the active substance, on the layer containing the active substance.
Dette har den fordel at allerede ved første berøring med TTS vil munnslimhinnen eller tungen, enda før kontaminering med det egentlige virkestoffholdige sjiktet, blir man møtt av en ytterst motbydelig smaksopplevelse som gjør at man vil unngå ytterligere oralt kontaktopptak. This has the advantage that already on first contact with TTS, the oral mucosa or the tongue, even before contamination with the actual active substance-containing layer, will be greeted by an extremely disgusting taste experience that will make you want to avoid further oral contact absorption.
Således kan det videre etter tiltak gjøres bruk av at stoffet ytterligere blir påført i et separat, fortrinnsvis meget tynt sjikt på baksjiktet. På denne måten blir det på sikrere måte oppnådd en videre intensivering av forbitringseffektene. Thus, after measures, use can be made of the substance being further applied in a separate, preferably very thin, layer on the back layer. In this way, a further intensification of the embitterment effects is achieved in a safer way.
Videre kan man således se for seg at de separate sjiktene på stoffet blir påført i en tykkelse mellom 10 og 100 um, fortrinnsvis mellom 5 og 20 um. Furthermore, one can thus envisage that the separate layers of the material are applied to a thickness between 10 and 100 µm, preferably between 5 and 20 µm.
En spesielt foretrukket utførelsesform av oppfinnelsen foreslår, at det blir anvendt et stoff som forårsaker en irritasjon som brenning av slimhinnen i munnhule og tunge. En negativ erfaring som engang er opplevd vil kunne være tilstrekkelig, til at et barn eller en stoffmisbruker vil varig avstå fra ytterligere forsøk med oral kontakt med en TTS. For øvrig kan en liknende virkning også bli oppnådd, når det blir anvendt et stoff, som forårsaker en intensiv bitter smak og særlig en ettersmak. A particularly preferred embodiment of the invention proposes that a substance is used which causes an irritation such as burning of the mucous membrane in the oral cavity and tongue. A negative experience experienced once could be sufficient for a child or a drug addict to permanently refrain from further attempts at oral contact with a TTS. Incidentally, a similar effect can also be achieved when a substance is used, which causes an intensive bitter taste and especially an aftertaste.
En virkningsfull utforming av et transdermalt system i følge oppfinnelsen er at det for naturering henholdsvis forbitring (denaturering) av minst et sjikt av en TTS som bitterstoff blir anvendt motbydelige smakende substanser som gallesyre, kinin, tannin, angostura, koffein (pur), lobelin, tetreolje, visse skimmelsoppkulturer, forbitrede eller sammenløpne substanser, terpentin eller ammoniakk. An effective design of a transdermal system according to the invention is that for the naturalization or embittering (denaturation) of at least one layer of a TTS as a bitter substance, disgusting tasting substances such as bile acid, quinine, tannin, angostura, caffeine (pur), lobeline, tea tree oil, certain mold cultures, embittered or confluent substances, turpentine or ammonia.
For å gjennomføre en utførelsesform blir det foreslått at stoffene som blir anvendt til forbitring blir innarbeidet i et overtrekks]'ikt, med hvilken det virkestoffholdige sjikt og enkeltvis også baksjiktet blir overtrukket. Således blir det som en spesielt foretrukket løsning foreslått at det blir anvendt et overtrekksjikt som er oppløselig i væsken i munnen. In order to carry out an embodiment, it is proposed that the substances used for embitterment are incorporated into a coating composition, with which the layer containing the active ingredient and, individually, also the back layer are coated. Thus, as a particularly preferred solution, it is proposed that a covering layer is used which is soluble in the liquid in the mouth.
Det transdermal terapeutiske systemet er ukomplisert og virksomt, og beskytter bam og/eller stoffmisbrukere mot utillatelig oral anvendelse av toksiske innholdsstoffer i et transdermalt terapeutisk system. På denne måten løser TTS i følge oppfinnelsen på optimal måte den innledningsvis stilte oppgaven. The transdermal therapeutic system is uncomplicated and effective, and protects children and/or drug addicts against the impermissible oral use of toxic ingredients in a transdermal therapeutic system. In this way, according to the invention, TTS solves the initially set task in an optimal way.
Claims (12)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19743484A DE19743484C1 (en) | 1997-10-01 | 1997-10-01 | Transdermal patches containing substance with unpleasant taste |
| PCT/EP1998/005955 WO1999016428A1 (en) | 1997-10-01 | 1998-09-18 | Method for preventing the misuse of a transdermal therapeutic system |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20001492D0 NO20001492D0 (en) | 2000-03-22 |
| NO20001492L NO20001492L (en) | 2000-03-22 |
| NO319163B1 true NO319163B1 (en) | 2005-06-27 |
Family
ID=7844345
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20001492A NO319163B1 (en) | 1997-10-01 | 2000-03-22 | Transdermal therapeutic system that prevents abuse |
| NO20001691A NO20001691L (en) | 1997-10-01 | 2000-03-31 | Childproof packaging for pressure sensitive products that also have a relatively large surface area, such as transdermal therapeutic systems (TTS) |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20001691A NO20001691L (en) | 1997-10-01 | 2000-03-31 | Childproof packaging for pressure sensitive products that also have a relatively large surface area, such as transdermal therapeutic systems (TTS) |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP1019032B1 (en) |
| JP (2) | JP4755338B2 (en) |
| KR (1) | KR100552102B1 (en) |
| AT (1) | ATE228356T1 (en) |
| AU (1) | AU759609B2 (en) |
| CA (1) | CA2305432C (en) |
| DE (2) | DE19743484C1 (en) |
| DK (1) | DK1019032T3 (en) |
| ES (1) | ES2188021T3 (en) |
| HK (1) | HK1029919A1 (en) |
| HU (1) | HU226644B1 (en) |
| ID (1) | ID24333A (en) |
| IL (1) | IL134479A (en) |
| MY (1) | MY116425A (en) |
| NO (2) | NO319163B1 (en) |
| NZ (1) | NZ503643A (en) |
| PL (1) | PL193066B1 (en) |
| PT (1) | PT1019032E (en) |
| SK (1) | SK3332000A3 (en) |
| TR (1) | TR200000461T2 (en) |
| TW (1) | TW431894B (en) |
| WO (1) | WO1999016428A1 (en) |
| ZA (1) | ZA988904B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19743484C1 (en) * | 1997-10-01 | 1999-01-28 | Lohmann Therapie Syst Lts | Transdermal patches containing substance with unpleasant taste |
| GB0026137D0 (en) * | 2000-10-25 | 2000-12-13 | Euro Celtique Sa | Transdermal dosage form |
| US7867511B2 (en) * | 2004-01-23 | 2011-01-11 | Travanti Pharma Inc. | Abuse potential reduction in abusable substance dosage form |
| DE102004019916A1 (en) * | 2004-04-21 | 2005-11-17 | Grünenthal GmbH | Anti-abuse drug-containing patch |
| CN112823191A (en) * | 2018-10-17 | 2021-05-18 | 日荣新化株式会社 | Adhesive sheet and method for producing same |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8804164D0 (en) * | 1988-02-23 | 1988-03-23 | Tucker J M | Bandage for administering physiologically active compound |
| US5236714A (en) * | 1988-11-01 | 1993-08-17 | Alza Corporation | Abusable substance dosage form having reduced abuse potential |
| US5149538A (en) * | 1991-06-14 | 1992-09-22 | Warner-Lambert Company | Misuse-resistive transdermal opioid dosage form |
| DE4342174C1 (en) * | 1993-12-10 | 1995-05-11 | Lohmann Therapie Syst Lts | Transdermal therapeutic system and a method for producing a transdermal therapeutic system for the combined transdermal application of physostigmine and scopolamine for the prophylaxis and pretreatment of poisoning by highly toxic organophosphorus neurotoxins, in particular Soman and its use |
| DE19743484C1 (en) * | 1997-10-01 | 1999-01-28 | Lohmann Therapie Syst Lts | Transdermal patches containing substance with unpleasant taste |
-
1997
- 1997-10-01 DE DE19743484A patent/DE19743484C1/en not_active Expired - Fee Related
-
1998
- 1998-09-18 PL PL339736A patent/PL193066B1/en not_active IP Right Cessation
- 1998-09-18 TR TR2000/00461T patent/TR200000461T2/en unknown
- 1998-09-18 HU HU0003476A patent/HU226644B1/en not_active IP Right Cessation
- 1998-09-18 EP EP98950053A patent/EP1019032B1/en not_active Expired - Lifetime
- 1998-09-18 JP JP2000513566A patent/JP4755338B2/en not_active Expired - Lifetime
- 1998-09-18 DE DE59806468T patent/DE59806468D1/en not_active Expired - Lifetime
- 1998-09-18 AU AU96265/98A patent/AU759609B2/en not_active Ceased
- 1998-09-18 DK DK98950053T patent/DK1019032T3/en active
- 1998-09-18 ID IDW20000399A patent/ID24333A/en unknown
- 1998-09-18 AT AT98950053T patent/ATE228356T1/en active
- 1998-09-18 PT PT98950053T patent/PT1019032E/en unknown
- 1998-09-18 SK SK333-2000A patent/SK3332000A3/en unknown
- 1998-09-18 WO PCT/EP1998/005955 patent/WO1999016428A1/en active IP Right Grant
- 1998-09-18 KR KR1020007003579A patent/KR100552102B1/en not_active IP Right Cessation
- 1998-09-18 NZ NZ503643A patent/NZ503643A/en not_active IP Right Cessation
- 1998-09-18 ES ES98950053T patent/ES2188021T3/en not_active Expired - Lifetime
- 1998-09-18 IL IL13447998A patent/IL134479A/en not_active IP Right Cessation
- 1998-09-18 CA CA002305432A patent/CA2305432C/en not_active Expired - Lifetime
- 1998-09-25 TW TW087115939A patent/TW431894B/en not_active IP Right Cessation
- 1998-09-29 MY MYPI98004449A patent/MY116425A/en unknown
- 1998-09-30 ZA ZA988904A patent/ZA988904B/en unknown
-
2000
- 2000-03-22 NO NO20001492A patent/NO319163B1/en not_active IP Right Cessation
- 2000-03-31 NO NO20001691A patent/NO20001691L/en not_active Application Discontinuation
-
2001
- 2001-01-15 HK HK01100389A patent/HK1029919A1/en not_active IP Right Cessation
-
2008
- 2008-08-20 JP JP2008212077A patent/JP2009035561A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7011843B2 (en) | Method for protecting a human being against health impairment by ingestion of a transdermal therapeutic system | |
| CN101384249B (en) | Disintegrable oral films | |
| US6210699B1 (en) | Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity | |
| US8999379B2 (en) | Transparent transdermal nicotine delivery devices | |
| US20090202597A1 (en) | Ache-Nmda Combination Wafer | |
| US20150086609A1 (en) | Adhesive label with bittering agent and fluidifying agents for natural airway secrettions | |
| AU2020303338A1 (en) | Transmucosal therapeutic system containing agomelatine | |
| NO319163B1 (en) | Transdermal therapeutic system that prevents abuse | |
| JPH07242536A (en) | Gelatin capsule agent containing essential oil component in skin | |
| SK9062000A3 (en) | Transmucosal formulations of levosimendan | |
| AU2004273574B2 (en) | Buccal formulations of galanthamine and uses thereof | |
| CZ20001025A3 (en) | Interception method of transdermal therapeutic system misuse | |
| MXPA00002933A (en) | Method for preventing the misuse of a transdermal therapeutic system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |